News Daily News JACC Debuts Data Digest on CV Health in the United States Caitlin E. Cox January 12, 2026
News Daily News Better LDL Control After STEMI Means Less Neoatherosclerosis Yael L. Maxwell December 23, 2025
News Daily News FDA Approves Lerodalcibep for Adults With Hypercholesterolemia Yael L. Maxwell December 15, 2025
News Conference News AHA 2025 Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia Caitlin E. Cox November 08, 2025
News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Conference News AHA 2025 CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia Todd Neale November 08, 2025
News Daily News ACC: It’s Time for Clinicians to Address Inflammation in CVD Caitlin E. Cox October 03, 2025
News Conference News ESC 2025 ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients Michael O'Riordan September 10, 2025
News Conference News ESC 2025 Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b Caitlin E. Cox August 31, 2025
News Daily News Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION Michael O'Riordan June 04, 2025
News Daily News AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease Caitlin E. Cox May 06, 2025
News Daily News Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI Michael O'Riordan April 22, 2025
News Daily News Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care Michael O'Riordan February 27, 2025
News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024
News Daily News Low Adherence to Secondary Prevention Recommendations Worldwide: INTERASPIRE Yael L. Maxwell September 23, 2024
News Conference News ESC 2024 Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events Michael O'Riordan September 01, 2024
News Conference News ACC 2024 NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year Yael L. Maxwell July 03, 2024
News Daily News ApoB Can Be High, Risky for ASCVD Even When LDL’s Normal Yael L. Maxwell June 17, 2024